Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, epithelial neoplasm, glioma, medulloblastoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Phase 1	2026-07-30		NCT03598244

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Hospital Colorado	Aurora	United States	312
Children's Hospital Los Angeles	Los Angeles	United States	226
Children's Hospital of Pittsburgh of UPMC	Pittsburgh	United States	120
Children's National Medical Center	Washington D.C.	United States	177
Cincinnati Children's Hospital Medical Center	Cincinnati	United States	405
Hospital for Sick Children	Toronto	Canada	76
Lucile Packard Children's Hospital Stanford University	Palo Alto	United States	66
Lurie Children's Hospital-Chicago	Chicago	United States	82
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Nationwide Children's Hospital	Columbus	United States	309
Saint Jude Children's Research Hospital	Memphis	United States	73
Texas Children's Hospital	Houston	United States	187